On October 16, 2017 CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody therapeutics for the treatment of cancer, reported that preclinical results will be presented at the 2017 AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper). The conference will take place October 26-30 in Philadelphia (Press release, CytomX Therapeutics, OCT 16, 2017, View Source [SID1234520962]).
Abstract Information:
Title: EGFR-CD3 bispecific Probody therapeutic induces tumor regressions and increases maximum tolerated dose >60 fold in preclinical studies
Session Category: EGFR/Her2
Date: Saturday, October 28
Time: Poster Session A: 12:30 p.m. – 4:00 p.m.
Location: Hall E, Pennsylvania Convention Center
Abstract: A164
The EGFR-CD3 bispecific Probody therapeutic poster will also be included in the Spotlight on Proffered Papers session starting at 10:50 a.m. on Friday, October 27 in the Terrance Ballroom, 400 level.
Title: Optimizing a CD71-targeting Probody drug conjugate (PDC) for activity in multiple solid tumor and lymphoma models and for tolerability in nonhuman primates
Session Category: Therapeutic Agents: Biological
Date: Sunday, October 29
Time: Poster Session B: 12:30 p.m. – 4:00 p.m.
Location: Hall E, Pennsylvania Convention Center
Abstract: B116
Title: A multi-analyte HPLC-MS/MS approach to assessing exposure of a Probody drug conjugate (PDC) in preclinical studies
Session Category: Therapeutic Agents: Biological
Date: Sunday, October 29
Time: Poster Session B: 12:30 p.m. – 4:00 p.m.
Location: Hall E, Pennsylvania Convention Center
Abstract: B103
Title: Nonclinical safety evaluation of two distinct second generation variants of anti-CTLA4 monoclonal antibody, ipilimumab, in monkeys
Session Category: Therapeutic Agents: Biological
Date: Sunday, October 29
Time: Poster Session B: 12:30 p.m. – 4:00 p.m.
Location: Hall E, Pennsylvania Convention Center
Abstract: LB-B33